Gibson Christopher 4

What Happened Christopher Gibson, a director of Pacific Biosciences of California, Inc. (PACB), was granted two awards on April 8, 2026: 57,473 restricted stock units (RSUs) and 77,842 derivative awards (totaling 135,315 units). Both grants were reported as acquisition code "A" at $0.00 per share (no cash paid at grant). These are compensatory awards tied to his board service rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-04-08; Filing date: 2026-04-10 (filed timely).
• Grant amounts and price: 57,473 RSUs @ $0.00 and 77,842 derivative awards @ $0.00 (total 135,315 units).
• Shares owned after transaction: Not stated in the filing.
• Footnotes / vesting:
  • F1 (RSUs): The 57,473 RSUs vest in equal annual installments on March 3 of 2027, 2028 and 2029, subject to continued service.
  • F2 (derivative award/option-like): One-third of the 77,842 shares vest on March 3, 2027, then the remainder vests in equal monthly installments over the following 24 months, subject to continued service.
• No indication of a 10b5-1 plan, tax-withholding sale, or immediate sale of shares in this filing.

Context These grants follow Mr. Gibson’s election to the board on March 3, 2026, and represent typical director compensation rather than a market buy or sell. Awards at $0.00 reflect issuance terms, not market value; actual economic value depends on PACB’s share price as the awards vest. For retail investors, such grants signal alignment of the director’s interests with shareholders but do not by themselves indicate a personal market view.